(0.29%) 5 114.96 points
(0.30%) 38 353 points
(0.34%) 15 983 points
(-0.94%) $83.06
(5.36%) $2.03
(0.30%) $2 354.20
(0.56%) $27.69
(4.29%) $961.70
(-0.26%) $0.932
(-0.45%) $10.97
(-0.58%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system...
Stats | |
---|---|
本日の出来高 | 7 098.00 |
平均出来高 | 157 075 |
時価総額 | 240.28M |
EPS | $0 ( 2024-03-14 ) |
次の収益日 | ( $-0.550 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.41 |
ATR14 | $0.0440 (0.78%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Humer Kristian | Buy | 275 000 | Stock Option (Right to buy) |
2024-04-16 | Humer Kristian | Buy | 0 | |
2024-03-11 | Cavalie Fanny | Sell | 11 000 | Common Stock |
2024-01-24 | Gottschalk Adrian | Buy | 300 000 | Stock Option (right to buy) |
2024-01-24 | Cardama Alfonso Quintas | Buy | 60 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
43.04 |
Last 90 transactions |
Buy: 4 432 955 | Sell: 2 595 211 |
ボリューム 相関
Foghorn Therapeutics Inc. 相関 - 通貨/商品
Foghorn Therapeutics Inc. 財務諸表
Annual | 2023 |
収益: | $34.16M |
総利益: | $25.49M (74.64 %) |
EPS: | $-2.34 |
FY | 2023 |
収益: | $34.16M |
総利益: | $25.49M (74.64 %) |
EPS: | $-2.34 |
FY | 2022 |
収益: | $19.23M |
総利益: | $19.21M (99.90 %) |
EPS: | $-2.62 |
FY | 2021 |
収益: | $1 319.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.00274 |
Financial Reports:
No articles found.
Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。